Rathore, Tuseeaf

Rathore, Tuseeaf was paid $788K by Medicaid between Jan 2018 and Feb 2018, across 3 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 50% of everything it billed.

33Billing provider infoRATHORE, TUSEEAF
IRVINGTON, NJ 07111

33aNPI1467854372assigned 09/23/2014

33bProvider typeClinical Medical Laboratory

28Total paid$788K

24GClaims7,859

24DCodes billed3

24AFirst – last monthJan 2018 – Feb 2018

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#69 of 122

Median peer was paid$1.29M

This provider vs. median0.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	7,859	$788K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	50%	4,538	2,460	$391K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	40%	2,441	1,749	$314K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	11%	880	472	$83K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.